Renaissance Technologies LLC Decreases Stock Position in Fulgent Genetics, Inc. $FLGT
Renaissance Technologies LLC significantly reduced its stake in Fulgent Genetics, Inc. by 78.3% in Q1 2026, selling 64,864 shares and retaining 18,000 shares valued at $286,000. This divestment follows Fulgent Genetics' weaker-than-expected quarterly results, including an adjusted loss of $0.58 per share and revenue below analyst estimates. Analyst sentiment remains cautious, with an average "Hold" rating and recent downgrades.
Fulgent Genetics (NASDAQ:FLGT) Share Price Crosses Below Fifty Day Moving Average - Here's What Happened
Fulgent Genetics (NASDAQ:FLGT) saw its share price drop below its 50-day moving average, trading as low as $18.96 before closing at $19.74. The company missed its quarterly earnings expectations, reporting an adjusted loss of $0.58 per share against an estimated loss of $0.46, and revenue of $85.39 million compared to a $94 million consensus. Analyst sentiment remains mixed with a consensus "Hold" rating and a price target of $27.50.
Fulgent Genetics, Inc. $FLGT Shares Purchased by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the first quarter, bringing its total holdings to 137,479 shares valued at $2.19 million. Institutional investors now own 48.06% of FLGT, while company insiders hold 36.18%, with recent insider sales primarily for tax obligations. Despite the increased institutional investment, analysts maintain a consensus "Hold" rating with a $27.50 price target, following the company's miss on quarterly revenue and EPS estimates and ongoing negative profitability.
Discipline and Rules-Based Execution in FLGT Response
This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 98.2:1 risk-reward setup, targeting a 28.2% gain versus 0.3% risk. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various time horizons.
Fulgent Genetics, Inc. $FLGT Shares Sold by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly reduced its stake in Fulgent Genetics (NASDAQ:FLGT) by 24.4% in the first quarter, selling over 217,000 shares. This comes as Fulgent Genetics reported a quarterly loss and revenue below analyst expectations, contributing to a "Hold" consensus rating among analysts. Despite some institutional investors increasing their holdings, corporate insiders also sold shares, primarily to cover tax obligations.
Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4 million, up 4% year-over-year, but revised its full-year revenue guidance downward to $330-$340 million due to lower collection rates from a complex billing system transition. The company also reported an adjusted EBITDA loss of $17.1 million. Despite these challenges, Fulgent Genetics is advancing its therapeutic pipeline, with its lead oncology candidate FID-007 moving towards a Phase III trial, and is expanding its anatomic pathology services through recent acquisitions and AI integration.
Wall Street Zen Downgrades Fulgent Genetics (NASDAQ:FLGT) to Strong Sell
Wall Street Zen has downgraded Fulgent Genetics (NASDAQ:FLGT) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "hold" with a $27.50 price target. This downgrade follows Fulgent's recent quarterly earnings report, which missed analyst expectations for both EPS and revenue. Insiders have sold a significant number of shares, though some institutional investors have increased their holdings.
Price to sales forward of Fulgent Genetics, Inc. – MUN:7F0
This page from TradingView provides financial information for Fulgent Genetics, Inc. (MUN:7F0), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or a placeholder, as no specific values or detailed data regarding the price-to-sales metric are visible.
Fulgent Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:FLGT) 2026-08-07
This article presents the slide deck published by Fulgent Genetics, Inc. in conjunction with their Q2 2026 earnings call. The content is provided by Seeking Alpha's transcripts team, which publishes numerous quarterly earnings calls. The aim is to share transcript-related developments with readers.
Fulgent Genetics, Inc. (FLGT) Stock Price, News, Quote & History
This article provides a comprehensive overview of Fulgent Genetics, Inc. (FLGT), including its stock price, historical data, company profile, and financial performance. As of August 7, the stock closed at $19.14, up 3.18%. The company specializes in clinical diagnostic and therapeutic development solutions, offering a range of genetic and oncology tests, and is headquartered in El Monte, California.
Fulgent Genetics, Inc. (FLGT) stock price, news, quote and history
This article provides a detailed overview of Fulgent Genetics, Inc. (FLGT), including its current stock price, recent performance metrics, and key financial data. It also outlines the company's diagnostic and therapeutic solutions, target markets, and analyst ratings, alongside comparisons with similar companies in the healthcare sector.
FULGENT GENETICS INC : PIPER SANDLER RAISES TARGET PRICE TO $19.00 FROM $15.00
Piper Sandler has increased its target price for FULGENT GENETICS INC (FLGT.O) to $19.00, up from the previous $15.00. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The article briefly reports this change in target price.
FULGENT GENETICS INC : PIPER SANDLER RAISES TARGET PRICE TO $19.00 FROM $15.00
Piper Sandler has raised its target price for Fulgent Genetics Inc (FLGT.O) shares to $19.00 from $15.00. This update indicates a more optimistic outlook from the analyst firm regarding the company's future stock performance. The report was issued by Reuters on August 4, 2026.
FULGENT GENETICS INC : PIPER SANDLER RAISES TARGET PRICE TO $19.00 FROM $15.00
Piper Sandler has increased its target price for Fulgent Genetics Inc (FLGT.O) from $15.00 to $19.00. This update was reported by Reuters on August 4, 2026. The article itself is a brief announcement of this change.
Fulgent Genetics Inc (7F0) Q1 2024 Earnings Report - Results, Call & Slides
Fulgent Genetics Inc (7F0) has released its Q1 2024 earnings report, showing an actual EPS of -€0.01, beating the consensus EPS of -€0.28. The company's revenue for the quarter was €55.93M, missing the expected €56.69M, and showing a YoY revenue growth decline of 2.54%. The report includes details on the earnings call and slide deck, and provides a history of past earnings reports and future estimates.
Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Recommendation of "Hold" from Analysts
Analysts have issued a "Hold" consensus recommendation for Fulgent Genetics (NASDAQ:FLGT), with an average 12-month price target of $27.00. The company recently reported Q2 2026 revenue of $85.4 million, missing estimates, and a non-GAAP loss of $0.58 per share, which exceeded expectations. Management also lowered its full-year 2026 guidance, citing continued profitability and cash generation pressures.
Fulgent Genetics (NASDAQ:FLGT) Announces Quarterly Earnings Results
Fulgent Genetics (NASDAQ:FLGT) reported disappointing quarterly earnings, missing analyst estimates for both EPS and revenue due to revenue-cycle issues, including delayed billing and lower collection rates. The company also reduced its full-year 2026 guidance, forecasting lower revenue and negative non-GAAP EPS. Despite these setbacks, acquisitions and progress in its therapeutic pipeline offer potential offsets for future growth.
Fulgent Genetics (FLGT) Stock Price Slides As Losses Deepen Guidance Falls
Fulgent Genetics (FLGT) saw its stock price fall by approximately 18% after reporting a significant quarterly net loss of US$29.5 million and lowering its full-year guidance. The company's revenue increased slightly year-on-year, but profitability challenges persist, with widening losses and reduced non-GAAP gross margins. Analysts are now concerned about the company's persistent operating losses and cash burn.
Fulgent Genetics Inc reports results for the quarter ended June 30 - Earnings Summary
Fulgent Genetics Inc (FLGT) has released its earnings summary for the quarter ended June 30. The report, provided by Refinitiv, gives an overview of the company's financial performance. Full access to the article is available through a TradingView subscription.
Fulgent Genetics cuts FY26 revenue guidance amid billing delays
Fulgent Genetics reported Q2 2026 revenue of $85.4 million and a non-GAAP loss of $16.2 million, missing analyst estimates. The company lowered its full-year 2026 revenue guidance to $330-$340 million and non-GAAP loss to $63-$67 million, attributing the revisions to delays in its billing system transition. Despite strong cash reserves of $551.5 million and ongoing share repurchases, the revised outlook reflects significant margin compression and operational challenges.
Fulgent Genetics Q2 Earnings Call Highlights
Fulgent Genetics reported second-quarter 2026 revenue of $85.4 million, a 20% sequential increase, but faced challenges from billing system transition issues that pressured collections and gross margins, leading to a $29.5 million GAAP net loss. The company lowered its 2026 revenue guidance to $330 million-$340 million, citing weaker collection rates, slower new business growth, and a major customer bringing testing in-house. Despite these setbacks, Fulgent continues to advance integration efforts for acquisitions, develop an AI pathology tool, and progress its FID-007 and FID-022 drug candidates.
Fulgent Genetics (NASDAQ:FLGT) Updates FY 2026 Earnings Guidance
Fulgent Genetics (NASDAQ:FLGT) has updated its FY 2026 earnings guidance, projecting an EPS of -$2.35 to -$2.22 and revenue of $330 million to $340 million, which falls below consensus estimates. The company also missed Q2 earnings expectations, reporting an adjusted EPS of -$0.58 and revenue of $85.39 million. Analyst sentiment remains cautious, with a consensus "Hold" rating and a $27 average price target, while the stock recently traded at $20.21.
Fulgent Genetics Inc (FLGT) Financial Health: Profitability & Balance Sheet Analysis
Fulgent Genetics Inc (FLGT) currently holds a financial score of 6.89, placing it 52nd out of 75 in the Healthcare Providers & Services industry, indicating stable financial health and high operating efficiency. Despite this, its latest quarterly revenue decreased by 3.16% year-over-year to $71.14M, and its net profit saw a significant year-over-year decrease of 115.32%. The article also notes that relevant financial data regarding cash, assets, liabilities, and free cash flow have not yet been disclosed by the company.
Behavioral Patterns of FLGT and Institutional Flows
This article analyzes behavioral patterns and institutional flows for Fulgent Genetics Inc. (NASDAQ: FLGT), suggesting a near-term neutral sentiment that may pause mid- and long-term weakness. It highlights an exceptional 96.0:1 risk-reward setup targeting a 26.9% gain with minimal risk. The report also provides AI-generated trading strategies with specific entry, target, and stop-loss zones for different risk profiles and holding periods, based on multi-timeframe signal analysis.
FLGT|Fulgent Genetics Inc|Price:19.941|Chg%:+0.301
This article provides a comprehensive stock analysis of Fulgent Genetics Inc (FLGT) by TradingKey. It highlights the company's relatively healthy fundamentals, significant growth potential, and fair valuation, positioning it 46th in the Healthcare Providers & Services industry. The analysis also notes high institutional ownership, a "Hold" rating from analysts with a target price of $15.00, and a sideways trading pattern suitable for range-bound swing trading despite strong fundamentals.
Fulgent Genetics Inc (FLGT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Fulgent Genetics Inc (FLGT), noting its score of 6.80, which ranks 25 out of 75 in the Healthcare Providers & Services industry. The company's beta of 0.93 indicates it tends to underperform in up markets but decline less in down markets. Key metrics like volatility, maximum drawdown, and Sharpe ratio are presented across various timeframes.
Fulgent Genetics Inc expected to post a loss of 46 cents a share - Earnings Preview
Fulgent Genetics Inc (FLGT) is projected to report a loss of 46 cents per share in its upcoming earnings announcement. This preview indicates the anticipated financial performance for the company, suggesting a negative earnings per share.
Fulgent Genetics CSO Gao Hanlin Executes Tax-Related Sale of 1,645 Shares at $19.67 on July 26, 2026
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (NASDAQ: FLGT), sold 1,645 common shares at $19.67 each on July 26, 2026, to cover tax obligations. Following this transaction, Hanlin still directly owns 988,729 common shares in the genomics testing company. The sale was disclosed in a regulatory filing with the SEC.
Fulgent Genetics Inc (FLGT) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Fulgent Genetics Inc (FLGT), covering operating, investing, and financing activities. It presents financial data including net income, capital expenditures, and changes in working capital over several years. The report also includes FAQs explaining different types of cash flow and how to interpret them for FLGT.
Fulgent Genetics Inc (FLGT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Fulgent Genetics Inc (FLGT) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page displays various financial metrics and stock performance data for FLGT.
Fulgent Genetics Inc (FLGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Fulgent Genetics Inc (FLGT), categorized by business segments and regional contributions. For specific financial periods, it indicates the revenue proportions from Institutional, Insurance, and Patient segments, as well as from the United States and Foreign regions. The data highlights Institutional revenue and U.S. revenue as dominant contributors.
FLGT|Fulgent Genetics Inc|Price:19.670|Chg%:-0.310
Fulgent Genetics Inc (FLGT) trades at $19.670, showing a -1.55% change. The company has healthy fundamentals and significant growth potential, although its valuation is considered fairly valued within the Healthcare Providers & Services industry. One analyst rates FLGT as "Hold" with a target price of $15.00, indicating a potential downside.
Fulgent Genetics, Inc. Revenue Breakdown – FWB:7F0
Fulgent Genetics, Inc. (FWB:7F0) generated €274.73 million in revenue last year, with its Laboratory Services segment contributing the most at €274.35 million. The majority of the revenue, €252.49 million, originated from the United States. This financial overview highlights the company's key revenue streams and geographical performance.
Fulgent Genetics (FLGT.US) will release its earnings report after market close on July 30.
Fulgent Genetics (FLGT.US) is scheduled to release its next earnings report after the market closes on July 30. Investors and analysts will be watching for the company's financial performance.
Fulgent Genetics (FLGT) to Release Earnings on Thursday
Fulgent Genetics (FLGT) is scheduled to release its Q2 2026 earnings before market open on Thursday, July 30th, with analysts anticipating a loss of $0.46 per share on revenues of $94.0 million. Wall Street maintains a "Hold" rating for FLGT with a consensus price target of $27.00, despite recent analyst downgrades and sell ratings. Insider selling by executives and significant institutional ownership (48.06%) indicate mixed sentiment and continued interest from larger investors amid recent stock volatility.
(FLGT) Movement Within Algorithmic Entry Frameworks
This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT) using algorithmic frameworks, highlighting mixed sentiment and a mid-channel oscillation pattern. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis. The report also notes an exceptional risk-reward setup targeting a 27.6% gain.
Fulgent Genetics seen as undervalued with strong balance sheet and insider buying, rated soft Buy.
Fulgent Genetics is considered an undervalued long-term investment due to its robust balance sheet and prudent capital management, including recent share buybacks and insider purchases. The stock trades below its tangible book value, with estimated net assets per share providing a margin of safety. An analyst has issued a "soft Buy" rating, recommending share accumulation if the price falls to the mid-teens.
ETFs Investing in Fulgent Genetics, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Fulgent Genetics, Inc. (FLGT). The ETFs are sorted by their market value of FLGT holdings and include details such as issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. This information aims to help investors identify funds with exposure to Fulgent Genetics, Inc. stocks.
Y Intercept Hong Kong Ltd Invests $1.08 Million in Fulgent Genetics, Inc. $FLGT
Y Intercept Hong Kong Ltd recently invested $1.08 million in Fulgent Genetics, acquiring 67,697 shares, representing a 0.23% stake in the company. Institutional ownership remains significant at 48.06%, despite recent insider sales by COO Jian Xie and insider Hanlin Gao. Analyst consensus holds a "Hold" rating with an average price target of $27.00 for the genetic testing company.
(FLGT) Movement Within Algorithmic Entry Frameworks
This article analyzes Fulgent Genetics Inc. (FLGT) using algorithmic frameworks. It highlights strong near to mid-term sentiment, a weak long-term outlook, and an exceptional risk-reward setup targeting a 27.8% gain. The piece also details specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis generated by AI models.
FLGT - Fulgent Genetics Inc Forecast, Target Price
This article provides a detailed financial overview and forecast for Fulgent Genetics Inc (FLGT). It includes key metrics such as market capitalization, income, sales, earnings per share, and stock performance indicators. The report also highlights analyst recommendations and a target price for the company's stock.
Enterprise value to EBITDA forward of Fulgent Genetics, Inc. – NASDAQ:FLGT
This article provides access to the enterprise value to EBITDA forward data for Fulgent Genetics, Inc. (NASDAQ: FLGT) via the TradingView platform. It navigates through the financial metrics available for the company within the health services sector. The content primarily focuses on directing users to financial data rather
Price to earnings forward of Fulgent Genetics, Inc. – NASDAQ:FLGT
This article displays financial information for Fulgent Genetics, Inc. (NASDAQ: FLGT), focusing on its forward price-to-earnings ratio. The content is presented on a financial data platform, providing a snapshot of the company's valuation metric. It confirms that the market was closed at the time of viewing with no trades.
Enterprise value to EBIT forward of Fulgent Genetics, Inc. – NASDAQ:FLGT
This article presents financial information for Fulgent Genetics, Inc. (NASDAQ:FLGT), focusing on its enterprise value to EBIT forward metric. It appears to be a stub or preview from a financial data platform, providing a title but no detailed content beyond company identification and a mention of market data providers.
Enterprise value to EBIT forward of Fulgent Genetics, Inc. – BMV:FLGT
This article focuses on the enterprise value to EBIT forward metric for Fulgent Genetics, Inc. (BMV:FLGT). The content appears to be a financial data page from TradingView, offering an overview of the company's financial performance. It provides no analytical text but lists the metric's value and change, indicating it is a data point for financial analysis.
Price to sales forward of Fulgent Genetics, Inc. – BMV:FLGT
The article provides financial information for Fulgent Genetics, Inc. (BMV:FLGT), specifically focusing on its price-to-sales forward ratio. It seems to be a financial data snippet from TradingView, indicating the market status and offering various tools and resources related to financial analysis.
Enterprise value to revenue forward of Fulgent Genetics, Inc. – NASDAQ:FLGT
The article focuses on the enterprise value to revenue forward metric for Fulgent Genetics, Inc. (NASDAQ:FLGT). It appears to be a financial data snippet or a specific analytical view provided by TradingView, detailing a specific metric for the company.
Price to earnings forward of Fulgent Genetics, Inc. – BMV:FLGT
This article provides the "Price to earnings forward" metric for Fulgent Genetics, Inc. (BMV:FLGT). It indicates that the market was closed with no trades when the information was accessed. The content is presented within the context of TradingView's financial data platform.
Fulgent Genetics, Inc. Actuals & Estimates (NASDAQ:FLGT)
This article provides comprehensive financial data and analyst estimates for Fulgent Genetics, Inc. (NASDAQ: FLGT), covering income statements, balance sheets, cash flow, and valuation metrics. It highlights the stock's recent performance, including a 0.82% increase in the last 24 hours, and presents a uniform analyst price target of $15.00. The company's next earnings report is scheduled for July 31, 2026, with recent earnings showing a slight surprise.
How (FLGT) Movements Inform Risk Allocation Models
This article analyzes Fulgent Genetics Inc. (FLGT) using AI models to inform risk allocation. It highlights a positive near-term sentiment with potential for a broader shift, identifying specific support and resistance levels. The piece also outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—all with sophisticated risk management parameters.
